SOLTF (Nxera Pharma Co) FCF Margin % : 45.14% (As of Jun. 2024)

View and export this data going back to . Start your Free Trial

What is Nxera Pharma Co FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Nxera Pharma Co's Free Cash Flow for the three months ended in Jun. 2024 was $23.2 Mil. Nxera Pharma Co's Revenue for the three months ended in Jun. 2024 was $51.4 Mil. Therefore, Nxera Pharma Co's FCF Margin % for the quarter that ended in Jun. 2024 was 45.14%.

As of today, Nxera Pharma Co's current FCF Yield % is 1.79%.

The historical rank and industry rank for Nxera Pharma Co's FCF Margin % or its related term are showing as below:

SOLTF' s FCF Margin % Range Over the Past 10 Years
Min: -47.97 Med: 35.71 Max: 66.26
Current: 5.21

During the past 13 years, the highest FCF Margin % of Nxera Pharma Co was 66.26%. The lowest was -47.97%. And the median was 35.71%.

SOLTF's FCF Margin % is ranked better than
82.87% of 1045 companies
in the Biotechnology industry
Industry Median: -145.32 vs SOLTF: 5.21

Nxera Pharma Co FCF Margin % Historical Data

The historical data trend for Nxera Pharma Co's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nxera Pharma Co FCF Margin % Chart

Nxera Pharma Co Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

32.50

51.65

38.92

61.98

-47.97

Nxera Pharma Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
FCF Margin %	Get a 7-Day Free Trial															-53.10	-15.98	-48.88	45.14	15.80

Competitive Comparison of Nxera Pharma Co's FCF Margin %

For the Biotechnology subindustry, Nxera Pharma Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nxera Pharma Co's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nxera Pharma Co's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Nxera Pharma Co's FCF Margin % falls into.

Nxera Pharma Co FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Nxera Pharma Co's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-42.533	/	88.664
	=	-47.97 %

Nxera Pharma Co's FCF Margin for the quarter that ended in Jun. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2024 )	/	Revenue (Q: Jun. 2024 )
	=	23.185	/	51.368
	=	45.14 %

Nxera Pharma Co FCF Margin % Related Terms

Thank you for viewing the detailed overview of Nxera Pharma Co's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Nxera Pharma Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nxera Pharma Co Ltd (OTCPK:SOLTF) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

4565:Japan JSS:Germany

Address

Midtown East, 9-7-2 Akasaka Minato-ku, Tokyo, JPN, 107-0052

Website

https://www.nxera.life

Nxera Pharma Co Ltd is a science and technology-led biopharmaceutical company. Its activities are drug discovery, drug development and the commercialization of pharmaceutical products. The focus is to discover new medicines for unmet medical needs, including novel small molecules, peptides and therapeutic antibodies targeting G Protein Coupled Receptors (GPCRs).